期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Iressa治疗晚期非小细胞肺癌15例观察

下载PDF
导出
摘要 目的观察Iressa对晚期耐药的非小细胞肺癌的疗效及不良反应。方法应用口服Iressa 250mg/d治疗晚期耐药非小细胞肺癌。结果15例晚期耐药非小细胞肺癌患者均全部完成口服Iressa 100d后评价疗效,有效4例,总有效率26.7%,其中PR4例(26.7%),SD例7(46.7%),PD4例(26.7%)。疾病控制率(CR+PR+SD)11例(73.3%)。中位肿瘤进展时间(TTP)5个月,中位生存时间6.5个月,1年生存率33.3%。主要不良反应为:皮疹、皮肤瘙痒、腹泻、食欲减退、恶心呕吐等。无心电图及肝肾功能改变。未出现因严重副作用导致中断治疗或死亡。结论Iressa治疗晚期耐药非小细胞肺癌疗效确切,虽有不良反应,但可耐受。
作者 顾贤成 鲁治文 金俊
机构地区 江苏省宜兴市人民医院肿瘤内科
出处 《临床医学工程》 2008年第12期87-88,共2页 Clinical Medicine & Engineering
关键词 IRESSA 耐药非小细胞肺癌 不良反应 靶向治疗
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献7

  • 1Herbst RS;Giaccone G;Schiller JH.Geffinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer:a phase Ⅲ Hal-INTACT 2[J],2004(05).
  • 2Giaceone G;Herbst RS;Manegold C.Gefitinib in combination with gemcitabine and gemcitabine and cisplatin in advanced non-small-cell lung cancer:A phase Ⅲ tria-MNTACT 1[J],2004(05).
  • 3Mendelsohn J;Baselga J.Status of epidermal growth factor receptorantagonists in the biology and treatment of cancer[J],2003(14).
  • 4郑迪,山鸟忠宏,平岛智德,瓜生恭章,松井薰,新田隆,小林政司,笹田真滋,潼本宜之,古川贡,大场雄一郎,周彩存.Iressa单药治疗化疗失败后的晚期非小细胞肺癌[J].中国肺癌杂志,2004,7(4):313-317. 被引量：10
  • 5孔进,陈良安,田庆,范保星,梁志欣,王平,于国.Iressa治疗中晚期非小细胞肺癌30例的分析[J].军医进修学院学报,2006,27(6):409-411. 被引量：1
  • 6Rosell R;Gatzemeier U;Betticher DC.Phase Ⅲ randomized trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell Lung cancer:A cooperative multinational trial[J],2002(10).
  • 7Schiller JH;Harrington D;Belani C P.Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J],2002(02).

二级参考文献28

  • 1Douillard JY, Giaccone G, Horai T et al. Improvement in disease related symptoms and quality of life in patients with advanced nonsmall-cell lung cancer (NSCLC) treated with ZD 1839 (Iressa) (I-DEAL 1). Proc Am Soc Clin Oncol,2002,21: 299a.
  • 2Kris MG, Natle RB, Herbst RS et al. A phase trial of ZD 1839 (Iressa) in advanced non-small-cell lung cancer (NSCLC) patients who had failed platinum-and docetaxel-based regimens (IDEAL 2).Proc Am Soc Clin Oncol,2002,21 : 292a.
  • 3Natale RR, Skarin AT, Maddox AM et al. Improvement in symp toms and quality of life for advanced non-small-cell lung cancer patients receiving ZD 1839 (Iressa) in IDEAl 2. Proc Am Soc Clin Oncol,2002,21 : 292a (Al167).
  • 4Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res,2001,7(5) : 1459-1465.
  • 5Herbst RS, Maddox AM, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J C
  • 6Rowinsky EK. The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target based anticancer agents.Drugs,2000,60(Suppl 1): 1-14; discussion 41-2.
  • 7Muthuswamy SK, Gilman M, Brugge JS. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol,1999,19(10) : 6845-6857.
  • 8Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell,1997,91(2) : 231-241.
  • 9Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science, 1998, 282(5392): 1318-1321.
  • 10Burgering BM, Coffer PJ. Protein kinase B (c-Akt) in phosphati dylinositol-3-OH kinase signal transduction. Nature, 1995, 376(6541) : 599-602.

共引文献9

临床医学工程
2008年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部